CN116018145A - 药物组合物和使用其治疗癌症的方法 - Google Patents

药物组合物和使用其治疗癌症的方法 Download PDF

Info

Publication number
CN116018145A
CN116018145A CN202180052939.0A CN202180052939A CN116018145A CN 116018145 A CN116018145 A CN 116018145A CN 202180052939 A CN202180052939 A CN 202180052939A CN 116018145 A CN116018145 A CN 116018145A
Authority
CN
China
Prior art keywords
effective amount
venetoclax
decitabine
chiduridine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052939.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·欧加内斯安
金姆-希恩·达奥
H·科尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dapeng Pharmaceutical Co ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN116018145A publication Critical patent/CN116018145A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180052939.0A 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法 Pending CN116018145A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Publications (1)

Publication Number Publication Date
CN116018145A true CN116018145A (zh) 2023-04-25

Family

ID=81384423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052939.0A Pending CN116018145A (zh) 2020-10-29 2021-10-27 药物组合物和使用其治疗癌症的方法

Country Status (10)

Country Link
US (1) US20230405037A1 (https=)
EP (1) EP4237094A4 (https=)
JP (1) JP2023548303A (https=)
KR (1) KR20230097034A (https=)
CN (1) CN116018145A (https=)
AU (1) AU2021369508A1 (https=)
CA (1) CA3188316A1 (https=)
MX (1) MX2023003305A (https=)
TW (1) TW202227096A (https=)
WO (1) WO2022093930A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024229073A1 (en) * 2023-05-02 2024-11-07 Otsuka Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIAN A.JONAS，等: "How we use venetoclax with hypomethylating agentsfor the treatment of newly diagnosed patients with acute myeloid leukemia", BLOOD CANCER JOURNAL, vol. 33, no. 12, 18 October 2019 (2019-10-18), pages 2796 *
GUILERMO GARCIA-MANERO，等: "Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomizedcrossover study", BLOOD, vol. 136, no. 06, 6 August 2020 (2020-08-06), pages 675 *
XIAORONG GU，等: "Decitabine- and 5-azacytidine resistance emergesfrom adaptive responses of the pyrimidine metabolism network", BLOOD CANCER JOURNAL, vol. 35, no. 04, 7 August 2020 (2020-08-07), pages 1033 *

Also Published As

Publication number Publication date
WO2022093930A1 (en) 2022-05-05
EP4237094A4 (en) 2024-07-10
US20230405037A1 (en) 2023-12-21
EP4237094A1 (en) 2023-09-06
TW202227096A (zh) 2022-07-16
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
JP2023548303A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7742841B2 (ja) デシタビンとセダズリジンとの組み合わせの固形経口剤形
US12065494B2 (en) Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US20230226040A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
US11938143B2 (en) Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
CN116018145A (zh) 药物组合物和使用其治疗癌症的方法
HK40084686A (en) Pharmaceutical compositions and methods of using the same for treating cancer
JP2024531799A (ja) 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法
US20190142786A1 (en) Methods of treating obesity in responder and non-responder populations
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
CN1317971A (zh) 包含拉米夫定和阿巴卡维的抗病毒联合用药物
HK40105549A (zh) 用地西他滨和西达尿苷治疗骨髓增生异常综合症的方法
HK40121574A (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40082478B (en) Solid oral dosage forms comprising decitabine and cedazuridine
HK40082478A (en) Solid oral dosage forms comprising decitabine and cedazuridine
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084686

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20250825

Address after: Tokyo, Japan

Applicant after: Dapeng Pharmaceutical Co.,Ltd.

Country or region after: Japan

Address before: Tokyo, Japan

Applicant before: OTSUKA PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan

TA01 Transfer of patent application right